Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Biosimilars: SOP for Regulatory Compliance for GMOs – V 2.0

Posted on By


Biosimilars: SOP for Regulatory Compliance for GMOs – V 2.0


Standard Operating Procedure for Regulatory Compliance for GMOs in Biosimilar Development

Department Biosimilars
SOP No. SOP/BS/040/2025
Supersedes SOP/BS/040/2022
Page No. Page 1 of 13
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To define the procedure for complying with national and international regulations governing the use of Genetically Modified Organisms (GMOs) in biosimilar research and development, ensuring legal authorization, risk control, and biosafety documentation.

2. Scope

This SOP applies to all projects involving GMOs in the biosimilar lifecycle, from vector construction to cell banking, including submissions to regulatory authorities such as IBSC, RCGM, and DCGI.

3. Responsibilities

  • Regulatory Affairs Officer: Coordinates all submissions, approvals, and renewals with IBSC, RCGM, and GEAC.
  • Principal Investigator: Provides technical details and risk assessment documentation.
  • Biosafety Officer: Maintains records of compliance certificates, approvals, and biosafety audits.
See also  Biosimilars: SOP for Transformation and Electroporation - V 2.0

4. Accountability

The Quality Assurance Head is accountable for ensuring that all GMO work is authorized and documented in accordance with the Biosafety Rules, 1989 under the EPA Act and that no unauthorized genetic engineering activities are carried out.

5. Procedure

5.1 Institutional Biosafety Committee (IBSC) Approval

  1. Submit the following documents:
    • Form I (as per DBT format)
    • Risk Assessment Report
    • GMO Details: Vector, Host, Insert
  2. Obtain signed minutes of IBSC approval and retain a copy in the GMO Compliance Folder (Annexure-1).

5.2 RCGM Submission

  1. Applicable for:
    • Scale-up of recombinant DNA work
    • Animal studies
    • Field trials
  2. Submit Form III to RCGM with:
    • Detailed project report
    • IBSC approval copy
    • Environmental risk management plan
  3. Track submission and follow up for approval. Document communication in RCGM Submission Log (Annexure-2).
See also  Biosimilars: SOP for Cell Culture Media Optimization - V 2.0

5.3 Compliance Documentation

  1. Maintain hard and soft copies of:
    • IBSC Minutes
    • RCGM Clearance Letters
    • Import/Export NOC (if applicable)
    • Biosafety Level (BSL) Certifications
  2. Log each activity involving GMOs in the GMO Activity Register (Annexure-3).

5.4 Audit Readiness

  1. Update regulatory matrix every quarter.
  2. Conduct mock audits using the GMO Compliance Checklist (Annexure-4).

6. Abbreviations

  • IBSC: Institutional Biosafety Committee
  • RCGM: Review Committee on Genetic Manipulation
  • GEAC: Genetic Engineering Appraisal Committee
  • DCGI: Drug Controller General of India

7. Documents

  1. GMO Compliance Folder (Annexure-1)
  2. RCGM Submission Log (Annexure-2)
  3. GMO Activity Register (Annexure-3)
  4. GMO Compliance Checklist (Annexure-4)

8. References

  • Biosafety Rules, 1989 under EPA Act, Govt. of India
  • WHO Biosafety Manual, 4th Edition
  • CDSCO Guidance on rDNA Products

9. SOP Version

Version: 2.0

See also  Biosimilars: SOP for Restriction Enzyme Digestion and Mapping - V 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: GMO Compliance Folder Index

Document Type Date Submitted To Filed By Location
IBSC Minutes 01/04/2025 IBSC Secretariat Rajesh Kumar Folder-A

Annexure-2: RCGM Submission Log

Submission ID Date Project Title Status Remarks
RCGM-040-2025 02/04/2025 CHO Cell Line Evaluation Under Review Follow-up on 10/05

Annexure-3: GMO Activity Register

Date Activity GMO ID Location Person Responsible
01/05/2025 MCB Expansion GMO-CHO-K1 BSL-2 Lab Sunita Reddy

Annexure-4: GMO Compliance Checklist

Checklist Item Status Comments
IBSC Approval on File Yes Valid till 31/03/2026
RCGM Approval (if needed) Pending Expected in May 2025
Biosafety Certificates Yes Lab audited March 2025

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Updated RCGM submission formats and annexures Regulatory revision
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: API Manufacturing: SOP for TLC Plate Preparation and Result Interpretation – V 2.0
Next Post: Aerosol: SOP for Performance Qualification (PQ) of Aerosol Crimping Machines – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version